TickerFacts.

Scinai Immunotherapeutics Ltd. (SCNI): Depreciation & Amortization

Annual figures by period end, from SEC filings.

$1.42M
Year ended 2025-12-31
+36.2%
3-year compound annual growth
$1.65M2021-12-31: $471.0K2022-12-31: $562.0K2023-12-31: $514.0K2024-12-31: $1.65M2025-12-31: $1.42M$1.42M
2021-12-31 Depreciation & Amortization (USD) 2025-12-31
Period endedDepreciation & AmortizationChange YoYSource filing
2025-12-31$1.42M-13.8%2026-04-01, From 2025-01-01
2024-12-31$1.65M+220.8%2026-04-01, From 2024-01-01
2023-12-31$514.0K-8.5%2026-04-01, From 2023-01-01
2022-12-31$562.0K+19.3%2025-05-07, From 2022-01-01
2021-12-31$471.0Kn/a2024-05-15, From 2021-01-01

Depreciation & Amortization at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedDepreciation & AmortizationChange YoY
Scinai Immunotherapeutics Ltd. (SCNI)2025-12-31$1.42M-13.8%
Inhibrx Biosciences, Inc. (INBX)2025-12-31$2.48M+8.7%
Outlook Therapeutics, Inc. (OTLK)2025-09-30$117.1K+2.8%
Pluri Inc. (PLUR)2026-06-30$511.0K+61.7%
Prokidney Corp. (PROK)2025-12-31$6.58M+21.0%
ImageneBio, Inc. (IMA)2025-12-31$400.0K-63.6%
Cardiff Oncology, Inc. (CRDF)2025-12-31$364.0K-9.9%
Surrozen, Inc. (SRZN)2025-12-31$537.0K-62.8%
CRISPR Therapeutics AG (CRSP)2025-12-31$19.48M+1.1%

Compare SCNI, INBX, OTLK, PLUR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗